Shire Submits European Marketing Authorization Application (MAA) For Velaglucerase Alfa For The Treatment Of Type 1 Gaucher Disease

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has submitted a MAA to the European Medicines Agency for velaglucerase alfa, the company’s enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease. This is the third marketing application for velaglucerase alfa that has been submitted, with previous submissions in the United States and Canada.

source : www.medicalnewstoday.com

Related News:

• Diabetes Experts Call For Early, Integrated Treatment Approach To Help Prevent Complications And Improve Patient Outcomes
• Novel Stroke Treatment Passes Safety Stage Of UCI-Led Clinical Trial
• Reovirus may be a novel approach to prostate cancer treatment
• Auxilium Announces Availability Of XIAFLEXTM For The Treatment Of Dupuytren’s Contracture
• Enobia Pharma Taps McGill Expertise In Developing First Effective Treatment For Rare Genetic Disorder
• Novo Nordisk Receives FDA Approval For Norditropin® FlexPro® For Growth Hormone Treatment
• Advanced Cell Technology’s RPE Cells Granted Orphan Drug Status From FDA For Treatment Of Stargardt’s Macular Dystrophy
• Sunridge Receives Approval For Its Non-Invasive Glaucoma Treatment In China
• Gene Signature May Improve Colon Cancer Treatment
• Effective Prostate Cancer Treatment Discovery